Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

168 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.
Burgos-Vargas R, Cardiel M, Xibillé D, Pacheco-Tena C, Pascual-Ramos V, Abud-Mendoza C, Mahgoub E, Rahman M, Fan H, Rojo R, García E, Santana K. Burgos-Vargas R, et al. Among authors: rojo r. Reumatol Clin (Engl Ed). 2019 Jan-Feb;15(1):43-53. doi: 10.1016/j.reuma.2017.04.006. Epub 2017 May 25. Reumatol Clin (Engl Ed). 2019. PMID: 28552437 Free article. English, Spanish.
Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary.
Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U. Reich K, et al. Among authors: rojo r. Immunotherapy. 2023 Sep;15(13):975-980. doi: 10.2217/imt-2022-0306. Epub 2023 May 31. Immunotherapy. 2023. PMID: 37254941 Free article. Review.
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC, Cardiel MH, Citera G, Goecke A, Jaller JJ, Lomonte ABV, Miranda P, Velez P, Xibillé D, Kwok K, Rojo R, García EG. Radominski SC, et al. Among authors: rojo r. Reumatol Clin. 2017 Jul-Aug;13(4):201-209. doi: 10.1016/j.reuma.2016.04.010. Epub 2016 Jun 15. Reumatol Clin. 2017. PMID: 27317492 Free article. English, Spanish.
Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.
Castañeda OM, Romero FJ, Salinas A, Citera G, Mysler E, Rillo O, Radominski SC, Cardiel MH, Jaller JJ, Alvarez-Moreno C, Ponce de Leon D, Castelli G, García EG, Kwok K, Rojo R. Castañeda OM, et al. Among authors: rojo r. J Clin Rheumatol. 2017 Jun;23(4):193-199. doi: 10.1097/RHU.0000000000000498. J Clin Rheumatol. 2017. PMID: 28145906
An Integrated Analysis of the Safety of Tofacitinib in Psoriatic Arthritis across Phase III and Long-Term Extension Studies with Comparison to Real-World Observational Data.
Burmester GR, Curtis JR, Yun H, FitzGerald O, Winthrop KL, Azevedo VF, Rigby WFC, Kanik KS, Wang C, Biswas P, Jones T, Palmetto N, Hendrikx T, Menon S, Rojo R. Burmester GR, et al. Among authors: rojo r. Drug Saf. 2020 Apr;43(4):379-392. doi: 10.1007/s40264-020-00904-9. Drug Saf. 2020. PMID: 32006348 Free PMC article.
Dissociated Agonist of Glucocorticoid Receptor or Prednisone for Active Rheumatoid Arthritis: Effects on P1NP and Osteocalcin Pharmacodynamics.
Shoji S, Suzuki A, Conrado DJ, Peterson MC, Hey-Hadavi J, McCabe D, Rojo R, Tammara BK. Shoji S, et al. Among authors: rojo r. CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):439-448. doi: 10.1002/psp4.12201. Epub 2017 May 27. CPT Pharmacometrics Syst Pharmacol. 2017. PMID: 28556506 Free PMC article. Clinical Trial.
168 results